Idorsia Ltd (SWX:IDIA)
Switzerland · Delayed Price · Currency is CHF 5.77
+0.10 (1.67%)
Jun 22, 2026, 5:31 PM CET
Idorsia Revenue
Idorsia had revenue of 57.39M CHF in the quarter ending March 31, 2026, a decrease of -2.53%. This brings the company's revenue in the last twelve months to 219.10M, up 35.80% year-over-year. In the year 2025, Idorsia had annual revenue of 220.58M with 96.06% growth.
Revenue (ttm)
219.10M
Revenue Growth
+35.80%
P/S Ratio
6.61
Revenue / Employee
480.47K
Employees
487
Market Cap
1.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220.58M | 108.08M | 96.06% |
| Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
| Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
| Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
| Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 695.07M |
| Basilea Pharmaceutica AG | 232.38M |
| Santhera Pharmaceuticals Holding AG | 77.19M |
| Newron Pharmaceuticals | 17.81M |
| BioVersys AG | 3.18M |
| Molecular Partners AG | 681.00K |
| MindMaze Therapeutics Holding | 642.00K |
| Xlife Sciences AG | 275.31K |
Idorsia News
- 8 hours ago - Idorsia price target raised to CHF 4.50 from CHF 4 at Deutsche Bank - TheFly
- 13 days ago - Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon - GlobeNewsWire
- 21 days ago - Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology - GlobeNewsWire
- 21 days ago - New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension - GlobeNewsWire
- 6 weeks ago - Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026 - GlobeNewsWire
- 7 weeks ago - Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year - GlobeNewsWire
- 7 weeks ago - Idorsia Quarterly report: Q1 2026 - Filings
- 7 weeks ago - Idorsia Earnings release: Q1 2026 - Filings